title: Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?
authors.forename: Nicola
authors.initials: N
authors.lastname: Normanno
authors.forename: Massimo
authors.initials: M
authors.lastname: Di Maio
authors.forename: Francesco
authors.initials: F
authors.lastname: Perrone
authors.forename: Manuela
authors.initials: M
authors.lastname: Campiglio
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism; D015986:Confounding Factors, Epidemiologic; D066246:ErbB Receptors / Q000008:administration & dosage / Q000378:metabolism*; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib